Compare Abeona Therapeutics Inc (ABEO) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Omnicom Group Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.41 (market cap $421.19M), while Omnicom Group Inc. trades at $85.11 (market cap $23.58B). The key difference: Omnicom Group Inc. is far larger — about 56× Abeona Therapeutics Inc's market cap, and Omnicom Group Inc. pays a 3.72% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | OMC | |
|---|---|---|
Market Cap | $421.19M | $23.58B |
Sector | Health | Media |
52-Week High | $7.45 | $86.22 |
52-Week Low | $4.17 | $67.27 |
Enterprise Value | $276.10M | $31.66B |
Dividend Yield | — | 3.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
Omnicom Group (OMC) trades at $84.65, down 0.69% on the day, with a bullish technical outlook per moving averages but mixed oscillators. Recent Q2 2026 earnings beat expectations with $2.65 EPS, driven by 6.1% organic revenue growth and margin expansion post-Interpublic acquisition. The company maintains a 4% dividend yield and active buybacks, though high P/E of 232.3 reflects net income volatility.
Outlook is positive with analyst consensus target of $107.00 (27% upside), but risks include integration costs, debt increase, and competitive pressures. The stock offers value from synergy realization and AI-driven growth initiatives, yet investors must monitor execution on cost savings and organic growth sustainability amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
